Changing Natural History of HER2–Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies-Reference-Cited by-同舟云学术

Changing Natural History of HER2–Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies

Published:2018-02 Issue:1 Volume:18 Page:29-37
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Mounsey Louisa A.,Deal Allison M.,Keith Kevin C.,Benbow Julia M.,Shachar Shlomit S.,Zagar Timothy,Dees E. Claire,Carey Lisa A.^ORCID,Ewend Matthew G.,Anders Carey K.

Funder

National Cancer Institute

National Institutes of Health

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference18 articles.

1. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma;Bendell;Cancer,2003

2. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

3. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy;Ross;Stem Cells,1998

4. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases;Anders;Cancer,2011

5. CEREBEL (EGF111438): a phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer;Pivot;J Clin Oncol,2015

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial;Nature Medicine;2024-09-13

2. HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer;Cancer Research Communications;2023-09-25

3. Genetic analysis of oligo-recurrence breast cancer: correlation with clinical outcomes;BMC Cancer;2023-09-15

4. Nanomaterials with dual immunomodulatory functions for synergistic therapy of breast cancer brain metastases;Bioactive Materials;2023-09

5. Available Systemic Treatments and Emerging Therapies for Breast Cancer Brain Metastases;Current Treatment Options in Oncology;2023-04-18